BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Biotech Holdings Ltd. (BIOHF) Adds United Arab Emirates to Sucanon Distribution


11/27/2007 7:20:16 AM

VANCOUVER, Nov. 26 /PRNewswire-FirstCall/ - Biotech Holdings reports that it has signed an agreement (the "Agreement") with a private company (the "UAE Distributor"), pursuant to which, for a period of three years with an option to renew, the UAE Distributor will have an exclusive right to market and distribute Sucanon Type II Diabetes drug ("Sucanon") in the United Arab Emirates including Dubai.

Pursuant to the agreement, the UAE distributor will have the option of receiving Sucanon either in pre-mix form from Canada or in tableted form from the Company's contract tableter in Mexico.

The United Arab Emirates according to information quoted in the Globe and Mail newspaper November 14, 2007, page L6 and attributed to Diabetes Forecast magazine, published by the American Diabetes Association, has the world's second highest percentage of adults afflicted by Type II Diabetes, at 19.5 %, approximately one in five adults.

This release has been approved by the Board of Directors of Biotech Holdings Ltd.

Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management's best judgement as to what may occur in the future. However, actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions and may differ materially from what is expressed. There is no assurance that sales, once begun in any specific market, will be material.

CONTACT: Austin Rand at Biotech Holdings, 1-888-216-1111, or info@biotechltd.com. For background information on Biotech Holdings, or to receive news updates, see www.biotechltd.com

CONTACT: Austin Rand at Biotech Holdings, 1-888-216-1111, or
info@biotechltd.com. For background information on Biotech Holdings, or to
receive news updates, see www.biotechltd.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES